Trials / Terminated
TerminatedNCT00313261
Safety and Efficacy Study of L-FMAU in Chronic HBV Patients of L-FMAU-201 Placebo Group
An Open-Label, Phase II Study to Evaluate Safety, Tolerability, Antiviral Activity and Biochemical and Immunological Responses of L-FMAU (Clevudine) in Chronic Hepatitis B Patients of L-FMAU-201 Placebo Group
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Bukwang Pharmaceutical · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and antiviral activity of clevudine 30 mg QD for treatment of longer period (24 weeks) in patients chronically infected with HBV.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clevudine |
Timeline
- Start date
- 2003-06-01
- Completion
- 2005-02-01
- First posted
- 2006-04-12
- Last updated
- 2012-10-17
Locations
7 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00313261. Inclusion in this directory is not an endorsement.